Drug intelligence / Profile preview

norethynodrel + mestranol

Development stage
Phase 3
Lead developer
Pfizer
Modality
Small Molecules
Administration
Oral
01

Overview

**Norethynodrel + mestranol** is the first approved combined oral contraceptive pill (COCP), consisting of the progestin norethynodrel and the estrogen mestranol. It acts primarily by suppressing gonadotropins through estrogenic and progestational activities, inhibiting ovulation, and secondarily altering cervical mucus and endometrial receptivity to prevent pregnancy. Initially developed by G.D. Searle & Company and approved by the FDA in 1957 for menstrual disorders, it gained contraceptive indication in 1960; various formulations ranged from 2.5-10 mg norethynodrel with 0.075-0.15 mg mestranol, though higher early doses were linked to thromboembolic risks, prompting dose reductions in modern equivalents.[1][3][4]

Brand names
Norinyl 1/50
Other names
mestranol/norethynodrelnorethindrone and mestranol
02

Targets

AR (Adrenergic receptors)ER (Estrogen receptor)PR (Progesterone receptor)

Beyond the preview

Go deeper on norethynodrel + mestranol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on norethynodrel + mestranol.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call